These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 9150246)
1. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246 [TBL] [Abstract][Full Text] [Related]
2. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. van Vliet AK; Nègre-Aminou P; van Thiel GC; Bolhuis PA; Cohen LH Biochem Pharmacol; 1996 Nov; 52(9):1387-92. PubMed ID: 8937448 [TBL] [Abstract][Full Text] [Related]
3. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307 [TBL] [Abstract][Full Text] [Related]
5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861 [TBL] [Abstract][Full Text] [Related]
6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [TBL] [Abstract][Full Text] [Related]
7. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225 [TBL] [Abstract][Full Text] [Related]
8. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672 [TBL] [Abstract][Full Text] [Related]
9. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M; Rauli S; Galli Kienle M Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791 [TBL] [Abstract][Full Text] [Related]
13. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. Hughes AD J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. Tesfamariam B; Frohlich BH; Gregg RE J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074 [TBL] [Abstract][Full Text] [Related]
15. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Veerkamp JH; Smit JW; Benders AA; Oosterhof A Biochim Biophys Acta; 1996 Apr; 1315(3):217-22. PubMed ID: 8611662 [TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Hidaka Y; Eda T; Yonemoto M; Kamei T Atherosclerosis; 1992 Jul; 95(1):87-94. PubMed ID: 1642695 [TBL] [Abstract][Full Text] [Related]
18. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Serajuddin AT; Ranadive SA; Mahoney EM J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703 [TBL] [Abstract][Full Text] [Related]
19. Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro. van Vliet AK; van Thiel GC; Naaktgeboren N; Cohen LH Biochim Biophys Acta; 1996 Jun; 1301(3):237-41. PubMed ID: 8664334 [TBL] [Abstract][Full Text] [Related]
20. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Sindermann JR; Fan L; Weigel KA; Troyer D; Müller JG; Schmidt A; March KL; Breithardt G Atherosclerosis; 2000 Jun; 150(2):331-41. PubMed ID: 10856525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]